{"url_path":"/sec/uncy/8-k/2026-07-02/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-074678-index.html","accession_number":"0001213900-26-074678","cik":"0001766140","ticker":"UNCY","issuer_name":"Unicycive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-074678-index.html","primary_entity_key":"0001766140","primary_entity_name":"Unicycive Therapeutics, Inc."},"word_count":306,"has_tables":true,"body_markdown":"false\n0001766140\n\n0001766140\n\n2026-07-02\n2026-07-02\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nDC 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT\nREPORT**\n\n**Pursuant\nto Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n** **\n\nDate\nof Report (Date of earliest event reported): **July 2, 2026**\n\n  \n\n**Unicycive\nTherapeutics, Inc.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**Delaware**\n\n \n**001-40582**\n \n**81-3638692**\n\n(State\nor other jurisdiction\n \n (Commission\nFile Number)\n \nIRS\nEmployer\n\nof\nincorporation or organization)\n \n \n \nIdentification\nNo.)\n\n  \n\n**1975\nW. El Camino Real, Suite 204**\n\n**Mountain\nView, CA 94040**\n\n(Address\nof principal executive offices)\n\n \n\nRegistrant’s\ntelephone number, including area code: **(650) 351-4495**\n\n \n\n(Former\nname or former address, if changed since last report)\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class:** \n \n**Trading Symbol(s)** \n \n**Name of each exchange on which registered:** \n\nCommon\nStock \n \nUNCY \n \nNasdaq\nCapital Market \n\n \n\nCheck the\nappropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n \n\n☐Written\ncommunication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n  \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of\n1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). \n\n \n\nEmerging\ngrowth company  ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐"}